<DOC>
	<DOCNO>NCT01625559</DOCNO>
	<brief_summary>The purpose study : - To evaluate safety tolerability RPE cellular therapy patient SMD Group - When-MA09-hRPE cell transplantation evaluate safety surgical procedure . - In future study intend assess number transplant hRPE cell . - In past , MA09-hRPE cell therapy use study evaluate validity potential . - Homologous retinal pigment epithelial cell derive embryonic stem cell , future study drug use represent potential validity evaluate optimal dose .</brief_summary>
	<brief_title>Safety Tolerability MA09-hRPE Cells Patients With Stargardt 's Macular Dystrophy ( SMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Adult male female 20 year age . Clinical diagnosis advance SMD . The visual acuity eye receive transplant well hand movement . The visual acuity eye receive transplant well 24 ( 20/320 ) Early Treatment Diabetic Retinopathy Study ( ETDRS ) letter . History malignancy . History myocardial infarction previous 12 month . History diabetes mellitus . Any immunodeficiency . Any current immunosuppressive therapy intermittent low dose cortico steroid . Serologic evidence infection Hepatitis B , Hepatitis C , HIV . Current participation clinical trial . Participation within previous 6 month clinical trial drug ocular systemic administration . Any sightthreatening ocular disease . Any chronic ocular medication . Any history retinal vascular disease ( compromised bloodretinal barrier ) . Glaucoma . Uveitis intraocular inflammatory disease . Significant lens opacity medium opacity . Ocular lens removal within previous 3 month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>